The chemical production of active substances takes place in Geel. More specifically, this is the site of the large-scale, commercial production of active pharmaceutical ingredients (active substances) for medicines. This production occurs according to strict regulations. The Chemical Production in Geel is the launching pad and growth site of new Janssen products. 

An active pharmaceutical ingredient is the active component of a medicine. The site produces 59 different kinds of active ingredients and 3 semi-finished products. The Geel site produces about 60% of the total volume of small molecules for the Johnson & Johnson parent company. There are two types of active substances: – large and small molecules. 

Small molecules are the traditional ingredients and are the result of a chemical production process. They are then processed into their final administration form(s) at pharmaceutical production sites around the world. The next step is packaging, followed by delivery to patients through the distribution network.

GEELSITEJNJ_DRIESLUYTEN80.jpg

Better medicines, quicker to the patients 

69_Geel_CDPP_man_reactor.jpg

The ultramodern Chemical Development Pilot Plant (CDPP) in Geel represents the largest-ever investment of the parent company Johnson & Johnson in Belgium. The CDPP is responsible for three critical processes: the production of active ingredients for further research, the 'translation" of clinically developed substances into a product environment, and the product launch. The high-tech production park is equipped with the newest production techniques, aimed at producing medicines quickly, efficiently and with care for the environment and at making these medicines available to patients worldwide at an affordable price. Since 2011, Geel has been closely involved in the launch of 8 new products.

Since 2011, Geel has been closely involved in the launch of 8 new products.

Durabilité
Économique

Janssen believes that strong corporate results, correct policies and focused activities pave the way towards economic sustainability. 

Janssen must constantly reinvent itself in order to cope with the structural and economic changes that affect its environment. This is why Janssen is committed to build partnerships within an open innovation model, and to the continuous alignment of its cost-competitiveness by only developing medicines with a high therapeutic added value. 

For Janssen this means specifically: being focused and a leader in research & development, and being efficient and progressive in terms of production with the aim of bringing new therapeutic solutions to patients quicker and at less expense, and implementing a growth strategy to ensure our continued investment in all these areas.